Meta-Analysis
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 228-238
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.228
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis
Yue Yang, Kan-Zuo Fu, Gu Pan
Yue Yang, Gu Pan, Department of Gastroenterology III, Heilongjiang Provincial Hospital, Harbin 150036, Heilongjiang Province, China
Kan-Zuo Fu, Department of Nursing, The Second Hospital of Harbin, Harbin 150056, Heilongjiang Province, China
Co-first authors: Yue Yang and Kan-Zuo Fu.
Author contributions: Yang Y and Fu KZ wrote the manuscript; Yang Y, Fu KZ, and Pan G collected and analyzed the data; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gu Pan, BSc, Nurse, Department of Gastroenterology III, Heilongjiang Provincial Hospital, No. 405 Guogoli Street, Nangang District, Harbin 150036, Heilongjiang Province, China. pangu6196@126.com
Received: November 14, 2023
Peer-review started: November 14, 2023
First decision: December 8, 2023
Revised: December 19, 2023
Accepted: December 29, 2023
Article in press: December 29, 2023
Published online: January 27, 2024
Processing time: 71 Days and 23.6 Hours
Core Tip

Core Tip: Higher Oncostatin M (OSM) expression/levels are found to be associated with worse disease outcomes which shows that OSM can be used as a s surrogate marker of poor prognosis in inflammatory bowel disease patients treated with anti-tumor necrosis factor based therapies. Thus, OSM appears to be an attractive biomarker for patient selection and clinical decision-making. However, owing to the presence of heterogeneity in included studies, this evidence should be refined in future studies.